a Department of Drug Discovery and Development, Harrison School of Pharmacy , Auburn University , AL , USA.
b Zydus Research Centre , Ahmedabad , India.
Infect Dis (Lond). 2017 Jul;49(7):483-492. doi: 10.1080/23744235.2017.1296968. Epub 2017 Mar 6.
Dalbavancin, a recently approved glycopeptide antibiotic, whose disposition is not affected by renal function as compared to vancomycin is used to treat serious infections caused by Staphylococci and Streptococci including multiple drug-resistant strains. Although reviews of the pharmacodynamic and clinical efficacy of dalbavancin have been published, a comprehensive overview of the pharmacokinetic properties including distribution and disposition in animals and humans has not been published. The aim of this review is to summarize the pharmacokinetics of dalbavancin, which justifies the intravenous dosing regimens and to provide considerations and perspectives with regard to dosing strategies. It is concluded that dalbavancin, despite high protein binding offers pharmacokinetic benefits such as good tissue penetration and long half-life. Dalbavancin may be a drug of choice and replace more resource demanding intravenous drugs to treat serious infections in a hospital setting.
达巴万星，一种最近批准的糖肽类抗生素，与万古霉素相比，其药物代谢动力学不受肾功能影响，用于治疗由葡萄球菌和链球菌引起的严重感染，包括多种耐药菌株。虽然已经发表了关于达巴万星的药效学和临床疗效的评价，但尚未发表关于其在动物和人体内的分布和代谢的药代动力学特征的全面概述。本综述的目的是总结达巴万星的药代动力学，这证明了其静脉给药方案的合理性，并提供了关于给药策略的考虑和观点。结论是，尽管达巴万星具有高蛋白结合率，但它具有良好的组织穿透性和较长的半衰期等药代动力学优势。达巴万星可能是一种治疗选择，可以替代更需要资源的静脉用药物，用于治疗医院环境中的严重感染。
